P90rsk ser380

MET Tyr1234&1235 (#3077), NUMA1 Ser395 (#3429), phospho‐Ser/Thr‐Gln‐Gly (#6966), phospho‐Ser‐Gln (#9607), phospho‐Thr(Asp/Glu)X(Asp/Glu) (#BL4176), phospho‐Thr‐X‐Arg (#2351), CHEK1 Ser345 (#2341), CHEK1 (2G1D5; #2360S), p90RSK Ser380 (#9335), PathScan® (Cell Signaling Technology) Multiplex Western Cocktail I [phospho‐p90RSK, phospho‐Akt, phospho‐p44/42 MAPK (Erk1/2), phospho‐S6; #5301], cleaved caspase‐8 (Asp391; #9496), cleaved caspase‐3 (Asp175; #9661), 53BP1 (#4937), ACIN1 (#4934), cdc2 (#9116T), cell cycle‐dependent kinase 2 (CDK2; #2546T), H2AX (#7631S), 11 (#8967), SMC3 (#5696), and MET (#8198S and #4560) antibodies were all obtained from Cell Signaling Technology (Danvers, MA, USA). Histone H2AX Ser139 (#05‐636), ATM Ser1981 (#05‐740), histone H3 Ser10 (#06‐570), and β‐actin (#MAB1501) antibodies were obtained from Merck Millipore Corporation (Darmstadt, Germany). TIF1B (KAP1) Ser824 (#A300‐767A) antibody was purchased from Bethyl Laboratories, Inc. (Montgomery, TX, USA). SMC3 Ser1083 (#NB100‐653) and ATM (#NB100‐309) antibodies were obtained from Novus Biologicals (Littleton, CO, USA).

Protein lysates were collected and analyzed by western blot as previously described [42 (link)]. In brief, primary antibodies against p90RSK (Ser380) (Cell Signaling Technology, Danvers, MA, USA, 9341), p70 S6 Kinase (Thr389) (Cell Signaling Technology 9205), S6 ribosomal protein (Ser235/236) (Cell Signaling Technology, 4856), eIF4G (Ser1108) (Cell Signaling Technology, 2441), RVFV MP12 Antibody (IBT Bioservices, Rockville, MD, USA, 04-0001), or HRP-conjugated actin (Abcam, ab49900) were diluted 1:1000 in 5% bovine serum albumin in 1× TBS with 0.1% Tween-20 solution followed by the addition of the appropriate secondary antibody. The western blots were visualized by chemiluminescence using SuperSignal West Femto Maximum Sensitivity Substrate kit (ThermoScientific, Waltham, MA, USA) and a Bio Rad Molecular Imager ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA) [41 (link),42 (link)].